Asia Pacific genetic testing market size was valued at USD 2.98 billion in 2025 and is projected to reach from USD 3.39 billion in 2026 to USD 9.61 Billion by 2034, growing at a CAGR of 13.9% during the forecast period 2026-2034.
A genetic test is a type of medical testing that is carried out with the purpose of determining whether or not there have been any alterations to the chromosomal structure or the DNA sequence. Either the gene included within the DNA sequence can be directly recognised through the sequencing process or indirectly identified through a variety of methods of genetic testing. The use of genetic testing in the diagnosis of rare diseases and the practise of customised medicine is expanding at a rapid rate.
The pandemic caused by COVID-19 has had a substantial influence on the expansion of the market for genetic testing during the course of the crisis. According to the study report that was published in Genetics in Medicine 2020, all clinical genetic testing was halted, and consultations and counselling based on telemedicine were implemented worldwide. According to the findings of this research, a total of 156 clinical genetics and cancer patients as well as 112 pregnant patients were assessed over the course of one month at the Columbia University Irving Medical Center (CUIMC). In order to stop the spread of the SARS-CoV2 virus, the vast majority of genetic testing businesses have begun using virtualization, and many of them also provide home testing kits and collect samples from patients in their own homes. However, according to the research article that was published in the Journal of Medical Genetics 2020, there was a hindrance reported in accessing genetic testing blood draws. As a consequence of this hindrance, the genetic testing was tremendously impacted, wherein a reduction in genetic testing from 97.7% to 74.1% was observed during the period in which virtual care was provided. As a result, it is anticipated that COVID-19 will have both a direct and an indirect influence on the market for genetic testing during the current crisis time.
In addition, the growing number of technology improvements that have occurred over the course of the previous few years have made various prospects for market development available. The rapid expansion of the market is being aided by a number of factors, including an increase in the incidence of chronic illnesses and the creation of specialised testing kits for specialised treatment areas. According to the World Population Prospects 2020 Highlights published by the United Nations, there will be more than 1.5 billion people over the age of 65 years by the year 2050, which is an increase from 727 million in the year 2020. Because of the rising number of elderly people and their increased risk of developing chronic illnesses, there has been an uptick in the need for preventative diagnostics, in particular genetic testing.
The increased attention that governments of various countries are placing on regulating genetic testing and raising knowledge about them has effectively resulted in a speedier acceptance of these tests all around the world. Increased spending on research and development, along with large firms' already established footholds in the market, has made it difficult for new companies to break into the industry. Maintaining a competitive advantage in the market requires a number of critical characteristics to be satisfied, including innovation in product design, improvement in quality, and strong distribution relationships. For instance, in August 2020, Ricoh Company Ltd. and DNA Chip Research Inc. produced RICOH Standard DNA Series EGFR mutation Type001, which is a reference DNA plate to be utilised in the blood-based genetic testing in the diagnosis of lung cancer. This plate is intended to be used by many companies.
Download a Free Sample To learn more about this report,
Integration of Genetic Testing with Electronic Health Records
Integration of genetic testing with electronic health records is improving access to genomic information by allowing clinicians to view test results alongside patient histories and treatment data. The transition toward connected genomic and clinical records supports faster interpretation of genetic findings and more informed care decisions, with Singapore’s National Precision Medicine Programme using genomic data to support clinical implementation across healthcare settings. This integration strengthens the use of genetic testing in routine care and supports more personalized treatment pathways.
Pharmacogenomic Testing in Clinical Care
The Asia Pacific Genetic Testing Market analysis shows that pharmacogenomic testing is gaining clinical relevance as healthcare providers use genetic information to guide medication selection and reduce adverse drug reactions. The transition toward pre-emptive testing allows clinicians to identify genetic risks before prescribing, with Singapore reporting that about one in four participants carried a variant associated with side effects to at least one medication. This shift supports safer prescribing and strengthens the role of pharmacogenomics in personalized clinical care.
Development of Local Genomic Testing Laboratories and Availability of Genetic Counseling Services Drive Market
Local genomic laboratories provide hospitals and healthcare providers with greater access to genetic testing services within their own countries.Regional testing capacity can reduce reliance on overseas laboratories, while shorter sample-transport times support faster test processing.The availability of local facilities also allows providers to offer tests for inherited disorders, cancer risk, and other genetic conditions to a broader patient base.For example, Singapore’s National Precision Medicine program supports local genomic testing and sequencing capabilities for clinical and research applications.Stronger regional laboratory capacity expands the supply of genetic testing services across Asia Pacific.
Genetic counseling helps patients and families understand test options, results, inheritance patterns, and potential health implications.Greater access to trained counselors can improve patient acceptance of genetic testing by providing professional guidance before and after testing.Hospitals and specialized clinics can therefore integrate counseling with hereditary cancer, reproductive, and rare-disease testing services.For example, Singapore’s National Cancer Centre provides genetic counseling for patients who undergo hereditary cancer risk assessment.Wider counseling availability supports the appropriate use of genetic tests and broadens their clinical adoption.
Privacy and data security concerns create risks around the storage, sharing, and unauthorized access of sensitive genetic information. These concerns can make patients and healthcare providers more cautious about genetic testing and data sharing. This hesitation can limit test uptake and slow adoption across healthcare settings.Complex genetic test interpretation requires specialized expertise to assess variants and translate results into clinically useful information. Limited availability of trained professionals can make result interpretation slower and increase the burden on healthcare providers.This complexity can restrict the use of advanced genetic tests and limit broader market adoption.
AI-Assisted Genetic Variant Interpretation and Genetic Testing Solutions for Preventive Healthcare Offers Growth Opportunities
Clinical laboratories, genetic testing providers, and healthcare institutions are key beneficiaries, as AI tools help interpret complex genomic data and support faster clinical reporting. AI-based interpretation platforms create revenue avenues through software licensing, laboratory integration, and subscription-based analysis services. Companies such as QIAGEN and Tempus offer AI-enabled genomic data and variant interpretation solutions.
Hospitals, diagnostic laboratories, healthcare providers, and preventive-care programs can use genetic testing to identify inherited risks before symptoms appear. Testing providers can generate new revenue through risk-assessment panels, screening programs, and personalized prevention services. Companies such as Invitae and Color Health have developed genetic testing services that support preventive and risk-based healthcare, contributing to market growth.
Differences in quality-control practices, testing procedures, and result interpretation can make genetic test outcomes less consistent between laboratories. These variations can increase validation requirements for companies and slow the wider deployment of standardized testing platforms.
Polymerase Chain Reaction (PCR) remains an established molecular technique because it enables rapid and sensitive amplification and detection of genetic material. Next Generation Sequencing supports detailed genetic analysis and is increasingly used in clinical and genomic applications across the region. Cytogenetics supports the identification of chromosomal abnormalities in genetic and clinical investigations. Microarrays enable simultaneous analysis of multiple genetic markers and support applications such as disease and genomic profiling. Others include additional molecular and genetic technologies that complement established testing techniques.
Request Customizationto receive a tailored report.
Ancestry & Ethnicity applications use genetic information to assess population origins and ancestry relationships. Traits Screening helps identify genetic variations associated with selected inherited traits and characteristics. Genetic Disease Carrier Status testing helps identify individuals who carry variants associated with inherited disorders. New Baby Screening supports early identification of selected genetic and inherited conditions in newborns. Others include additional genetic testing applications across healthcare, research, and personalized medicine.
Consumables include reagents, kits, and other laboratory materials required for genetic testing workflows. Equipment includes analyzers, sequencing systems, PCR instruments, and other laboratory platforms used for genetic testing. Software & Services support data analysis, interpretation, laboratory management, reporting, and other services associated with genetic testing.
Hospitals & Clinics use genetic testing to support diagnosis, screening, treatment decisions, and personalized healthcare. Diagnostic Laboratories provide specialized genetic testing services and process samples received from healthcare providers and patients. Others include research institutions, academic organizations, and other healthcare settings that use genetic testing for clinical and research purposes.
Speak to an Analystto discuss market opportunities.
The Asia Pacific Genetic Testing Market accounted for the largest regional share of 20.6% in 2025. The region benefits from expanding genetic testing adoption across healthcare, research, and preventive screening applications. Advancements in sequencing technologies and increasing healthcare investment further support market growth.
Japan’s population aged 65 and over is projected to increase from 28.6% of the population in 2020 to 38.7% by 2070, supporting long-term demand for disease screening, preventive healthcare, and age-related genetic testing.China aims to increase average life expectancy from 79.25 years in 2025 to 80 years by 2030 while strengthening disease prevention and healthcare services, supporting future demand for genetic screening and precision healthcare.
South Korea’s elderly population is projected to increase from 8.15 million in 2020 to 13.06 million by 2030, creating greater potential demand for genetic testing linked to age-related diseases, screening, and personalized healthcare.India’s elderly population is projected to reach nearly 193 million by 2030, increasing the need for preventive healthcare, disease screening, and personalized healthcare services that can support genetic testing adoption.
The Asia Pacific Genetic Testing Market is moderately fragmented, with the market ecosystem comprising diagnostic laboratories, genetic testing companies, biotechnology firms, hospitals, research institutions, and specialized genomic service providers, reflecting a diverse market share.
Established players compete mainly through test accuracy, technology capabilities, broad testing portfolios, clinical validation, regulatory compliance, laboratory networks, and data interpretation services, while the market ecosystem includes emerging players that compete through specialized genetic panels, faster testing, localized services, affordable pricing, advanced sequencing technologies, and personalized testing solutions.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com